Bronchiectasis is not an interstitial lung disease. It is classified as a chronic obstructive lung disease, placing it in the same family as asthma, chronic bronchitis, and emphysema. The confusion between the two is understandable, though, because they can coexist in the same patient and even mimic each other on imaging. Understanding where each disease lives inside the lung makes the distinction clear.
Where Each Disease Occurs in the Lung
The core difference comes down to anatomy. Bronchiectasis is an airway disease. It involves permanent widening and damage to the bronchi, the branching tubes that carry air in and out of the lungs. Mucus pools in these stretched-out airways, leading to chronic infection and inflammation. The problem sits in the tubes themselves.
Interstitial lung disease (ILD) is a tissue disease. The interstitium is the thin, web-like scaffolding that surrounds the tiny air sacs where oxygen enters your blood. In ILD, this scaffolding becomes inflamed and scarred (fibrosed), making the lungs stiff and less able to exchange oxygen. The problem sits in the walls between the air sacs, not in the airways.
Because these diseases target different structures, they behave differently on breathing tests. Bronchiectasis causes obstruction, meaning air has trouble flowing out through damaged, mucus-clogged airways. ILD causes restriction, meaning the lungs can’t expand fully because scar tissue has made them rigid.
How Symptoms Differ
The hallmark symptom of bronchiectasis is a persistent cough that produces thick, often discolored mucus. This productive cough is the single most important clue that should raise suspicion. On examination, crackles are heard in about 70% of patients, and wheezing shows up in roughly 21% to 34%. Recurrent chest infections are common, sometimes several per year, and bacteria like Pseudomonas and Haemophilus frequently take up residence in the damaged airways.
ILD typically presents with a dry, nonproductive cough and progressive shortness of breath, especially during physical activity. Because the scarring reduces the lung’s ability to transfer oxygen, people with ILD often notice they get winded doing things that used to be easy. Crackles are also common in ILD, but the absence of significant mucus production is a key distinguishing feature.
How They Look on CT Scans
A high-resolution CT scan is the standard tool for diagnosing both conditions, and the patterns are distinct. In bronchiectasis, the airways appear abnormally wide compared to the blood vessels running alongside them. Radiologists look for a “signet ring” sign, where a dilated airway and its neighboring artery resemble a ring with a stone. Visible airways close to the outer edges of the lung, where they would normally be too small to see, are another giveaway. Mucus plugging may create a “tree-in-bud” pattern of tiny branching opacities.
In ILD, the signature findings involve the tissue between the air sacs rather than the airways. Ground-glass opacities (a hazy whiteness suggesting inflammation), reticulation (a fine net-like pattern of scarring), and honeycombing (clusters of small cysts indicating advanced fibrosis) are the features radiologists quantify to assess severity and predict outcomes.
Where It Gets Confusing: Traction Bronchiectasis
Here is where the two conditions genuinely overlap in a way that trips people up. When ILD progresses and scar tissue builds up around the airways, that scarring can physically pull the airways open, stretching them out of shape. This is called traction bronchiectasis, and it looks like bronchiectasis on a CT scan, but it is not the same disease.
In traction bronchiectasis, the surrounding scar tissue retracts and distends the airways, creating dilated bronchi as a secondary consequence of fibrosis. Medical guidelines explicitly exclude traction bronchiectasis from the clinical definition of bronchiectasis disease. The distinction matters because primary bronchiectasis is driven by a cycle of infection, inflammation, and mucus buildup, while traction bronchiectasis is driven by the fibrotic process of ILD. Patients with traction bronchiectasis typically don’t have the same pattern of chronic sputum production, frequent exacerbations, or persistent bacterial infections that define clinical bronchiectasis.
Research comparing the two has found that pathogenic bacteria in traction bronchiectasis patients were not associated with worse outcomes, reinforcing that this is a fundamentally different situation from the infection-driven cycle of true bronchiectasis, where organisms like Pseudomonas aeruginosa are linked to hospitalization rates of around 26% per year.
When Both Conditions Appear Together
Some systemic diseases can cause both bronchiectasis and ILD in the same person, which further blurs the line. Rheumatoid arthritis is a notable example. Lung involvement in rheumatoid arthritis can include ILD (scarring of the interstitium), bronchiectasis (airway damage), bronchiolitis (small airway inflammation), pleural disease, and pulmonary nodules. These can occur in various combinations.
Other connective tissue diseases, including systemic sclerosis and inflammatory myopathies, frequently associate with ILD and can also involve airway disease. When a patient has both conditions, each requires its own evaluation and treatment approach rather than being lumped together as a single problem.
Treatment Is Fundamentally Different
The management strategies for bronchiectasis and ILD reflect their different underlying mechanisms. For bronchiectasis, the treatment plan centers on breaking the cycle of mucus buildup and infection. Airway clearance therapy, involving techniques to physically move mucus out of the lungs, is recommended for all patients with clinically significant disease. Maintenance antibiotics may be needed for patients with frequent infections. Vaccinations against influenza and pneumococcal disease help prevent exacerbations, and any underlying cause (such as an immune deficiency) should be addressed when possible.
ILD treatment targets the inflammation and scarring process itself. Depending on the type and cause of ILD, this may involve medications that slow fibrosis or suppress the immune system’s attack on lung tissue. Airway clearance techniques, which are central to bronchiectasis management, play little role in ILD because the problem is tissue scarring rather than mucus-clogged airways.
Getting the classification right has real consequences for which treatments are offered and how the disease is monitored over time. If you have been told you have bronchiectasis, you have an obstructive airway disease, not an interstitial lung disease, even though the two can coexist or one can create features that resemble the other.